TPO-RA characteristics to consider*
Scroll left and right to view the full chart.
| Product characteristics | Avatrombopag1 | Eltrombopag2‡ | Romiplostim3§ |
|---|---|---|---|
Image
Image
Oral administration | |||
Image
Image
Bioavailability not impacted by food type | |||
Image
Image
Single dosage strength per formulation† | |||
Image
Image
No dose restrictions based on population ancestry demographics | |||
Image
Image
Additional formulation for kids (≥1 to <6) |
| ‡ |
Doptelet and Doptelet Sprinkle don’t require extra eye exams or liver function monitoring.1,4-6
Doptelet tablets and Doptelet Sprinkle are not substitutable on a mg-to-mg basis.1
Kid-friendly dosing
Single dosing strength per formulation enables greater dosing flexibility for patients to help meet treatment goals1,7†
Oral tablet
Oral granules
Increase dosage if platelet count is <50x109/L
Reduce dosage if platelet count is >200 and ≤400x109/L
Image
Dose level
Oral tablet
ages ≥6 years
Oral granules
ages ≥1 and <6 years
6
40 mg 1x per day
20 mg 1x per day
5
40 mg 3x per week, 20 mg on remaining days
20 mg 3x per week, 10 mg on remaining days
Starting dose
4
20 mg 1x per day
10 mg 1x per day
3
20 mg 3x per week
10 mg 3x per week
2
20 mg 2x per week OR 40 mg 1x per week
10 mg 2x per week OR 20 mg 1x per week
1
20 mg 1x per week
10 mg 1x per week
See more information on how to prepare and dose Doptelet Sprinkle.
Studied mixture options include liquids (water, whole milk, orange juice, etc) and soft foods (yogurt, applesauce, etc).1
Sprinkle does not dissolve in mixture.
- Select the recommended product (Doptelet tablets or Doptelet Sprinkle oral granules) based on the indication and patient’s age1
- Doptelet tablets and Doptelet Sprinkle are not substitutable on a mg-to-mg basis1
Doptelet tablets: Start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 20 mg 3 times a week; start patients taking moderate or strong dual inducers of CYP2C9 and CYP3A4 with 40 mg once daily.1
Doptelet Sprinkle: Start patients taking moderate or strong dual inhibitors of CYP2C9 and CYP3A4 with 10 mg (contents of 1 capsule) 3 times a week; start patients taking moderate or strong dual inducers of CYP2C9 and CYP3A4 with 20 mg (contents of 2 capsules) once daily.1
Please see full Prescribing Information for additional information on dose adjustments.
Titration Calculator
This titration calculator is intended for use by healthcare professionals only as a guide for titrating Doptelet. It is not a substitute for professional medical judgment, clinical evaluation, or individualized patient assessment. Users are strongly advised to consult the Full Prescribing Information before making any dosing decisions.
Important Reminder: After initiating therapy with Doptelet or Doptelet Sprinkle, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts weekly for at least 4 weeks following discontinuation of treatment.
- Doptelet and Doptelet Sprinkle are not used to make platelet counts normal
- Do not exceed a daily dose of 40 mg for Doptelet (2 tablets) or a daily dose of 20 mg for Doptelet Sprinkle (content of 2 capsules)
Want more information on dosing and titration? Answer the following questions:
1
How old is your patient?
2
I’m looking for dosing recommendations for:
2
I’m looking for dosing recommendations for:
3
Is your patient taking moderate or strong dual inducers or moderate or strong dual inhibitors of CYP2C9 and CYP3A4?
4
My patient is taking:
*Dosing comparisons do not imply efficacy or safety.
†After initiating therapy with Doptelet or Doptelet Sprinkle, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts weekly for at least 4 weeks following discontinuation of treatment. Doptelet and Doptelet Sprinkle are not used to make platelet counts normal.1
‡Eltrombopag must be taken at least 2 hours before or 4 hours after other medications, calcium-rich foods, or supplements containing polyvalent cations. Some versions of eltrombopag do offer an additional suspension formulation.2
§Romiplostim requires office visits for treatment injections.3
TPO-RA=thrombopoietin receptor agonist.
Image
Help your patients access treatment
Find the support and resources you need to get your patients started on Doptelet or Doptelet Sprinkle.
Image
Connect with an expert
Get guidance on starting treatment, managing access, and supporting your patients taking Doptelet and Doptelet Sprinkle.
- DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc; 2025.
- Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2023.
- Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen; 2025.
- Data on file. Clinical study report for AVA-PED-301. 2025: Sobi, Inc.
- Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
- Bussel J, Allen LF, Aggarwal K, Vredenburg M, Tian W, Liebman W. Lack of clinically significant hepatotoxicity in patients with chronic immune thrombocytopenia treated with the novel, oral thrombopoietin receptor antagonist avatrombopag: pooled safety analysis of four clinical studies. Poster presented at: ISTH Conference 2019. July 6-10, 2019; Melbourne, Australia. Abstract PB0418.
- Kapoor DU, Garg R, Gaur M, et al. Pediatric drug delivery challenges: enhancing compliance through age-appropriate formulations and safety measures. J Drug Deliv Sci Technol. 2024;96:105720.